SEC Form 4 · accession 0001193125-26-267272
Metagenomi Therapeutics, Inc. · MGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurence Reid
Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 11, 2026 · 2:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001785279
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.23 | Jun 9, 2026 | A | 17,400 | A | — | Jun 8, 2036 | Common Stock | 17,400 | 17,400 | D |
Explanation of responses
- F1The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.